OverviewSuggest Edit

Kezar Life Sciences is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of novel small molecule therapeutics targeting protein homeostasis for autoimmune disorders. Kezar's lead drug candidate, KZR-616, leverages more than a decade of research directed by co-founder Christopher Kirk into the unique role of the immunoproteasome in immune cell biology. 
TypePublic
Founded2015
HQSouth San Francisco, US
Websitekezarlifesciences.com

Latest Updates

Employees (est.) (Feb 2019)24
Share Price (Nov 2020)$5.7
Cybersecurity ratingCMore

Key People/Management at Kezar Life Sciences

Franklin Berger

Franklin Berger

Director
John Fowler

John Fowler

Chief Executive Officer, Co-Founder and Director
Graham Cooper

Graham Cooper

Director
Jason Dinges

Jason Dinges

Director
Noreen Roth Henig

Noreen Roth Henig

Chief Medical Officer
Marc Belsky

Marc Belsky

Chief Financial Officer
Show more

Kezar Life Sciences Office Locations

Kezar Life Sciences has an office in South San Francisco
South San Francisco, US (HQ)
4000 Shoreline Ct #300
Show all (1)

Kezar Life Sciences Financials and Metrics

Kezar Life Sciences Revenue

USD

Net income (Q3, 2020)

(11.3m)

EBIT (Q3, 2020)

(11.6m)

Market capitalization (20-Nov-2020)

262.8m

Closing stock price (20-Nov-2020)

5.7

Cash (30-Sept-2020)

12.8m

EV

255.7m
Kezar Life Sciences's current market capitalization is $262.8 m.
Annual
USDFY, 2018FY, 2019

General and administrative expense

6.6m10.0m

R&D expense

18.1m27.4m

Operating expense total

24.7m37.3m

EBIT

(24.7m)(37.3m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

General and administrative expense

1.7m1.6m2.4m2.4m2.6m3.0m2.7m3.3m

R&D expense

5.2m4.7m5.9m6.9m7.1m7.5m7.1m8.3m

Operating expense total

7.0m6.3m8.3m9.4m9.7m10.5m9.9m11.6m

EBIT

(6.9m)(6.3m)(8.3m)(9.4m)(9.7m)(10.5m)(9.9m)(11.6m)
Annual
USDFY, 2018FY, 2019

Cash

24.2m15.0m

Prepaid Expenses

1.9m1.9m

Current Assets

109.8m81.1m

PP&E

4.6m4.3m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

102.0m39.6m18.5m13.0m20.4m20.6m17.3m12.8m

Prepaid Expenses

1.5m1.7m1.7m1.7m2.5m2.1m1.8m2.6m

Current Assets

120.6m115.3m103.8m96.2m88.8m126.5m160.6m153.8m

PP&E

4.8m4.7m4.8m4.7m4.5m4.1m3.9m3.7m
Annual
USDFY, 2018FY, 2019

Net Income

(23.2m)(35.1m)

Depreciation and Amortization

690.0k1.3m

Accounts Payable

1.4m2.2m

Cash From Operating Activities

(20.8m)(29.9m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(11.7m)(17.4m)(7.6m)(16.4m)(25.5m)(10.0m)(19.5m)(30.8m)

Depreciation and Amortization

281.0k486.0k303.0k628.0k961.0k362.0k731.0k1.2m

Accounts Payable

548.0k1.6m560.0k919.0k

Cash From Operating Activities

(10.7m)(15.3m)(6.7m)(14.4m)(22.7m)(8.3m)(18.4m)(27.6m)
USDQ2, 2018

Financial Leverage

1.1 x
Show all financial metrics

Kezar Life Sciences Acquisitions / Subsidiaries

Company NameDateDeal Size
Kezar Life Sciences Australia Pty Ltd

Kezar Life Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

SecurityScorecard logo

Kezar Life Sciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Kezar Life Sciences Online and Social Media Presence

Embed Graph

Kezar Life Sciences News and Updates

Kezar Life Sciences to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive team…

Kezar Life Sciences Reports Fourth Quarter and Year End 2018 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its fourth quarter and full…

Kezar Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its third quarter 2018 busine…

Kezar Life Sciences Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., June 20, 2018 /PRNewswire/ -- Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, announced today that it has priced its...

Kezar Life Sciences Blogs

Kezar Life Sciences to Present During Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will present during upcoming virtua…

Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates

FDA grants two Orphan Drug Designations to KZR-616 for the treatment of Dermatomyositis (DM) and Polymyositis (PM) KZR-616 clinical and pre-clinical data continues to support its potential to positively affect multiple drivers of immune-mediated diseases KZR-261 IND submission on-track for Q1…

Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020

Clinical and pre-clinical data continues to support potential of KZR-616 to positively effect multiple drivers of immune-mediated diseases SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing b…

Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences

– ACR and ASN presentations provide updated interim results from the Phase 1b MISSION study and highlight the broad immunomodulatory potential of KZR-616 to treat severe autoimmune diseases – Cytokines 2020 and SITC presentations to showcase Sec61 inhibition as a novel mechanism for blocking expr…

Kezar Life Sciences Frequently Asked Questions

  • When was Kezar Life Sciences founded?

    Kezar Life Sciences was founded in 2015.

  • Who are Kezar Life Sciences key executives?

    Kezar Life Sciences's key executives are Franklin Berger, John Fowler and Graham Cooper.

  • How many employees does Kezar Life Sciences have?

    Kezar Life Sciences has 24 employees.

  • Who are Kezar Life Sciences competitors?

    Competitors of Kezar Life Sciences include ConSynance, MAX BioPharma and Triumvira.

  • Where is Kezar Life Sciences headquarters?

    Kezar Life Sciences headquarters is located at 4000 Shoreline Ct #300, South San Francisco.

  • Where are Kezar Life Sciences offices?

    Kezar Life Sciences has an office in South San Francisco.

  • How many offices does Kezar Life Sciences have?

    Kezar Life Sciences has 1 office.